Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.376,19
0,60%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ GlycoMimetics Inc (GLYC) GlycoMimetics Inc (GLYC) Notizie

GLYC

GlycoMimetics (GLYC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLYC
DataOraFonteTitoloSimboloCompagnia
12/11/202414:00PR Newswire (US)Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024NASDAQ:GLYCGlycoMimetics Inc
07/11/202422:47Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
07/11/202422:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/11/202423:41Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
06/11/202413:00Business WireGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNASDAQ:GLYCGlycoMimetics Inc
04/11/202422:26Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GLYCGlycoMimetics Inc
04/11/202420:01Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
29/10/202415:00AllPennyStocks.comShares of Biotech Company Up Over 100% Premarket Following Merger & Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202415:00AllPennyStocks.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
29/10/202412:00Business WireGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaNASDAQ:GLYCGlycoMimetics Inc
29/10/202411:30Business WireGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointNASDAQ:GLYCGlycoMimetics Inc
15/08/202423:01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
14/08/202422:13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
08/08/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
25/07/202415:00Business WireGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanNASDAQ:GLYCGlycoMimetics Inc
04/06/202413:00Business WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
29/05/202422:01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
06/05/202412:00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202413:00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202412:00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202412:00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
26/02/202413:00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202413:00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202413:00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202413:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
10/12/202318:00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202313:00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202312:00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202314:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLYC

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network